AbbVie

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? (öffnet in neuem Tab)

  The Motley Fool · 01.10.2026

• AbbVie (ABBV) Stock May Be 41% Undervalued Following JUVMO Approval (öffnet in neuem Tab)

  Yahoo Finance · 01.10.2026

• AbbVie to Host Third-Quarter 2026 Earnings Conference Call (öffnet in neuem Tab)

  Investing News Network · 01.10.2026

• 
  5 Solid Dividend Stocks to Buy Now (öffnet in neuem Tab)

  24/7 Wall St. · 01.10.2026

• AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It (öffnet in neuem Tab)

  Zacks · 01.10.2026

• 5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test) (öffnet in neuem Tab)

  24/7 Wall St. · 01.10.2026

• ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? (öffnet in neuem Tab)

  Zacks · 01.10.2026

• Was The Run In JNJ Stock Hiding In Plain Sight? (öffnet in neuem Tab)

  Trefis · 30.09.2026

• AbbVie Stock: Buy, Sell, or Hold in October? (öffnet in neuem Tab)

  The Motley Fool · 30.09.2026

• Are You Overpaying For Pfizer Stock Versus Its Rivals? (öffnet in neuem Tab)

  Trefis · 30.09.2026

• What Does AbbVie (ABBV) Need To Prove After Its Eczema Drug And AI Update? (öffnet in neuem Tab)

  Simply Wall St. · 30.09.2026

• What Is Merck Stock's Biggest Opportunity? (öffnet in neuem Tab)

  Trefis · 30.09.2026

• 1 Profitable Stock to Keep an Eye On and 2 Facing Challenges (öffnet in neuem Tab)

  StockStory · 30.09.2026

• BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength (öffnet in neuem Tab)

  Yahoo Finance · 30.09.2026

• AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis (öffnet in neuem Tab)

  Seeking Alpha · 30.09.2026

• AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 (öffnet in neuem Tab)

  Yahoo Finance · 30.09.2026

• AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know (öffnet in neuem Tab)

  Yahoo Finance · 29.09.2026

• Defensive Dividends: 3 Companies Investors Can Rely On (öffnet in neuem Tab)

  Zacks · 29.09.2026

• Is Eli Lilly Stock a Good Fit For Your Portfolio Risk? (öffnet in neuem Tab)

  Trefis · 29.09.2026

• Final Trade: Abbvie, Advanced Micro, SpaceX, Eaton Corp. (öffnet in neuem Tab)

  CNBC · 29.09.2026

• Amazon, Walmart Surplus Auctioneer Climbs Toward A Breakout; Stock Up 45% (öffnet in neuem Tab)

  Investor's Business Daily · 29.09.2026

• Management Raised the Bar For Eli Lilly Stock; Does The Chart Agree? (öffnet in neuem Tab)

  Trefis · 29.09.2026

• AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval (öffnet in neuem Tab)

  GuruFocus.com · 29.09.2026

• AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says (öffnet in neuem Tab)

  Yahoo Finance · 29.09.2026

• AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo (öffnet in neuem Tab)

  Zacks · 29.09.2026

• ESPN unveils 2026 MLB Postseason coverage plans beginning with Wild Card Series presented by AbbVie (öffnet in neuem Tab)

  ESPN Press Room · 29.09.2026

• Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium (öffnet in neuem Tab)

  BioSpace · 29.09.2026

• AbbVie Teams Up With Valkai to Use AI in Clinical Development (öffnet in neuem Tab)

  Yahoo Finance · 29.09.2026

• AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development (öffnet in neuem Tab)

  Yahoo Finance · 29.09.2026

• The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell (öffnet in neuem Tab)

  Yahoo Finance · 29.09.2026